Tag: apellis pharmaceuticals

February 28, 2019

Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications

Apellis Pharmaceuticals (NASDAQ:APLS) has announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals. As...
December 21, 2018

Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA

Apellis Pharmaceuticals (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of...
December 20, 2018

Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy

Apellis Pharmaceuticals (Nasdaq:APLS) today provided an update on the status of its Phase 3 program for APL-2 in patients with Geographic...
December 4, 2018

Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study

Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition...